Newron sales and marketing update

The German Institute for Quality and Efficiency in Health Care (IQWiG) said data from Newron supporting Xadago safinamide were incomplete and that the “added benefit cannot be derived.” According to IQWiG, benefit evaluations could not be made because studies evaluating Xadago had different durations than studies evaluating a comparator therapy. ...